Research & Development

Novel MET Inhibition Boosts Immunotherapy for Lung Cancer
Research & Development Novel MET Inhibition Boosts Immunotherapy for Lung Cancer

Small cell lung cancer (SCLC) represents one of the most formidable challenges in oncology, characterized by its aggressive nature and a disheartening prognosis that leaves many patients with limited hope. Accounting for roughly 15% of lung cancer cases, this disease spreads rapidly and often

Can AI Diagnose Genetic Cholestasis in Infants Early?
Research & Development Can AI Diagnose Genetic Cholestasis in Infants Early?

Picture a scenario where a newborn’s routine liver test could instantly signal a rare genetic condition, slashing diagnostic delays and guiding medical teams toward the most effective care plan before irreversible damage sets in. This transformative possibility is becoming a reality with an

UHS Leads Respect and Heal Initiative for Safer Healthcare
Research & Development UHS Leads Respect and Heal Initiative for Safer Healthcare

In an era where healthcare settings are increasingly becoming battlegrounds for disruptive and violent incidents, a pressing need to protect both workers and patients has emerged as a critical priority across the nation. United Health Services (UHS), a prominent healthcare system based in New York

Can Stem Cell Therapy Revolutionize Autism Treatment?
Research & Development Can Stem Cell Therapy Revolutionize Autism Treatment?

What if a single medical breakthrough could alter the trajectory for millions of individuals with autism spectrum disorder (ASD)? Picture a child struggling to connect socially, or a family searching tirelessly for solutions beyond traditional therapies, and imagine a future where hope becomes

Can Ianalumab Redeem Novartis’ MorphoSys Acquisition?
Research & Development Can Ianalumab Redeem Novartis’ MorphoSys Acquisition?

What happens when a multi-billion-dollar corporate gamble teeters on the edge of failure, only to find a potential lifeline in an unexpected corner of science? In the high-stakes world of pharmaceuticals, Novartis is navigating this very scenario with ianalumab, a groundbreaking drug showing

IO Biotech's Cylembio Shows Promise Despite Trial Setback
Research & Development IO Biotech's Cylembio Shows Promise Despite Trial Setback

Imagine a world where melanoma, one of the deadliest forms of skin cancer, could be tackled with a groundbreaking vaccine that boosts existing treatments for patients who currently have limited options. This scenario lies at the heart of recent discussions surrounding IO Biotech's experimental

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later